PRESS INFORMATION BUREAU
पत्र सूचना कार्यालय
GOVERNMENT OF INDIA
भारत सरकार

Hindu, Delhi
Friday 31st January 2014, Page: 19
Width: 7.98 cms, Height: 3.21 cms, a4, Ref: pmin.2014-01-31.31.118

Cadila gets USFDA nod to sell arthritis drug

NEW DELHI: Cadila Healthcare, on Thursday, said it had received the final approval from the U.S. Food and Drug Administration (USFDA) to market Etodolac extended release tablets in strengths of 400 mg, 500 mg and 600 mg, the company said in a filing to the BSE. The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis. — PTI

Company